Clinical Trial Update: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B. [Phase 4]

View source ↗

Summary

Phase 4 study evaluating PEGASYS (peginterferon alfa-2a) plus entecavir in treatment-naive, HBeAg-positive chronic hepatitis B patients. The study status is com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• ENTECAVIR (ENTECAVIR)
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis B, Chronic | Phase 4 | Status: COMPLETED